3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Completed
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Sarcoma
1
Conditions
Breast Neoplasms
3
Wound Infection
2
Infections
2
Surgical Wound Infection
1
Laryngeal Neoplasms
1
Bone Neoplasms
1
Interventions
Voriconazole
4
Vancomycin
3
Fluconazole
3
Filgrastim
3
Ciprofloxacin
3
Caspofungin
3
liposomal amphotericin B
2
Trimethoprim, Sulfamethoxazole Drug Combination
2
Therapeutics
2
Piperacillin, Tazobactam Drug Combination
2
Peripheral Blood Stem Cell Transplantation
2
Melphalan
2
Itraconazole
2
Granulocyte Colony-Stimulating Factor
2
Fosfomycin
2
Daptomycin
2
Cyclophosphamide
2
Cefazolin
2
Antibiotic Prophylaxis
2
ziprasidone
1
threonic acid
1
telavancin
1
soybean oil, phospholipid emulsion
1
plerixafor
1
monalizumab
1
lime
1
human papillomavirus vaccine, L1 type 16, 18
1
fluorescein isothiocyanate-keyhole limpet hemocyanin
1
fludarabine phosphate
1
fish oil triglycerides
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Completed
×
Infections
×
Cefazolin
×
Clear all
NCT01479283
2021-03-11
PARITY
McMaster University
Phase 3
Completed
602 enrolled
NCT00867295
2010-06-02
TIVAD
Istanbul University
Phase 3
Completed
150 enrolled